strekin hearing loss drug

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss

BASEL, SWITZERLAND — Strekin AG, a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million (~$2.86M USD) from private investors. According to the announcement, the funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss,…

Read More
drug treatment hearing loss age related

New Drug Under Development to Prevent Age-Related Hearing Loss

TAMPA, FLORIDA — The first ever medication to treat age-related hearing loss could potentially receive FDA approval through a comprehensive study being conducted at the University of South Florida. Robert Frisina, PhD, chair of the USF Medical Engineering Department and director of the USF Global Center for Hearing and Speech Research, and his team were…

Read More
frequency therapeutics financing development fx-322

Frequency Therapeutics Raises $62 Million in Latest Financing Round to Support Hearing Loss Drug Development

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the closing of a $62.0 million Series C financing. Frequency will use the proceeds to support the clinical development of FX-322, a regenerative therapeutic…

Read More
sensorion hearing loss

Sensorion Receives FDA Investigational New Drug Clearance for Arazasetron (SENS-401)

MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced today that it has received the Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with SENS-401, based on…

Read More
sensorion gene therapy hearing loss

Sensorion Announces Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs for Hearing Loss

MONTPELLIER, FRANCE — French biotech firm Sensorion has announced the signature of a research partnership framework agreement with Institut Pasteur (Paris) granting to Sensorion an option to obtain exclusive licenses to develop and market drug candidates in gene therapy coming from collaborative projects, for the restoration, treatment and prevention of hearing disorders. In accordance with…

Read More
rinri hearing loss therapy

Rinri Therapeutics Secures $1.8M Seed Funding to Advance Novel Hearing Regeneration Therapy

SHEFFIELD, UNITED KINGDOM — Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, announced today that it successfully secured £1.4 million (approximately $1.8M USD) in seed funding. The financing, which was co-led by Boehringer Ingelheim Venture Fund and UCB Ventures and joined by BioCity, will support the ongoing growth of the…

Read More
hearing loss drug fx-322

Frequency Therapeutics Announces Positive Phase 1/2 Trial Results for Hearing Restoration Drug

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical…

Read More
decibel therapeutics

Decibel Therapeutics Appoints New Chief Medical Officer and COO

BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…

Read More
decibel therapeutics

Pharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics

Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…

Read More
frequency fx 322 fundraising

Frequency Therapeutics Completes $42 Million Series B Financing

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced earlier this month that it has closed $42 million in Series B financing. The latest funding round for the company, which is seeking to create a new class of drugs based on small molecule stimulation of dormant stem cells within the body, brings the total capital raised…

Read More